Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.
Journal
Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)
ISSN: 1545-8636
Titre abrégé: MMWR Surveill Summ
Pays: United States
ID NLM: 101142015
Informations de publication
Date de publication:
14 05 2021
14 05 2021
Historique:
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
14
7
2021
Statut:
epublish
Résumé
Adults are at risk for illness, hospitalization, disability and, in some cases, death from vaccine-preventable diseases, particularly influenza and pneumococcal disease. CDC recommends vaccinations for adults on the basis of age, health conditions, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults remains low. August 2017-June 2018 (for influenza vaccination) and January-December 2018 (for pneumococcal, herpes zoster, tetanus and diphtheria [Td]/tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis [Tdap], hepatitis A, hepatitis B, and human papillomavirus [HPV] vaccination). The National Health Interview Survey (NHIS) is a continuous, cross-sectional national household survey of the noninstitutionalized U.S. civilian population. In-person interviews are conducted throughout the year in a probability sample of households, and NHIS data are compiled and released annually. NHIS's objective is to monitor the health of the U.S. population and provide estimates of health indicators, health care use and access, and health-related behaviors. Adult receipt of influenza, pneumococcal, herpes zoster, Td/Tdap, hepatitis A, hepatitis B, and at least 1 dose of HPV vaccines was assessed. Estimates were derived for a new composite adult vaccination quality measure and by selected demographic and access-to-care characteristics (e.g., age, race/ethnicity, indication for vaccination, travel history [travel to countries where hepatitis infections are endemic], health insurance status, contacts with physicians, nativity, and citizenship). Trends in adult vaccination were assessed during 2010-2018. Coverage for the adult age-appropriate composite measure was low in all age groups. Racial and ethnic differences in coverage persisted for all vaccinations, with lower coverage for most vaccinations among non-White compared with non-Hispanic White adults. Linear trend tests indicated coverage increased from 2010 to 2018 for most vaccines in this report. Few adults aged ≥19 years had received all age-appropriate vaccines, including influenza vaccination, regardless of whether inclusion of Tdap (13.5%) or inclusion of any tetanus toxoid-containing vaccine (20.2%) receipt was measured. Coverage among adults for influenza vaccination during the 2017-18 season (46.1%) was similar to the estimate for the 2016-17 season (45.4%), and coverage for pneumococcal (adults aged ≥65 years [69.0%]), herpes zoster (adults aged ≥50 years and aged ≥60 years [24.1% and 34.5%, respectively]), tetanus (adults aged ≥19 years [62.9%]), Tdap (adults aged ≥19 years [31.2%]), hepatitis A (adults aged ≥19 years [11.9%]), and HPV (females aged 19-26 years [52.8%]) vaccination in 2018 were similar to the estimates for 2017. Hepatitis B vaccination coverage among adults aged ≥19 years and health care personnel (HCP) aged ≥19 years increased 4.2 and 6.7 percentage points to 30.0% and 67.2%, respectively, from 2017. HPV vaccination coverage among males aged 19-26 years increased 5.2 percentage points to 26.3% from the 2017 estimate. Overall, HPV vaccination coverage among females aged 19-26 years did not increase, but coverage among Hispanic females aged 19-26 years increased 10.8 percentage points to 49.6% from the 2017 estimate. Coverage for the following vaccines was lower among adults without health insurance compared with those with health insurance: influenza vaccine (among adults aged ≥19 years, 19-49 years, and 50-64 years), pneumococcal vaccine (among adults aged 19-64 years at increased risk), Td vaccine (among all age groups), Tdap vaccine (among adults aged ≥19 years and 19-64 years), hepatitis A vaccine (among adults aged ≥19 years overall and among travelers aged ≥19 years), hepatitis B vaccine (among adults aged ≥19 years and 19-49 years and among travelers aged ≥19 years), herpes zoster vaccine (among adults aged ≥60 years), and HPV vaccine (among males and females aged 19-26 years). Adults who reported having a usual place for health care generally reported receipt of recommended vaccinations more often than those who did not have such a place, regardless of whether they had health insurance. Vaccination coverage was higher among adults reporting ≥1 physician contact during the preceding year compared with those who had not visited a physician during the preceding year, regardless of whether they had health insurance. Even among adults who had health insurance and ≥10 physician contacts during the preceding year, depending on the vaccine, 20.1%-87.5% reported not having received vaccinations that were recommended either for all persons or for those with specific indications. Overall, vaccination coverage among U.S.-born adults was significantly higher than that of foreign-born adults, including influenza vaccination (aged ≥19 years), pneumococcal vaccination (all ages), tetanus vaccination (all ages), Tdap vaccination (all ages), hepatitis B vaccination (aged ≥19 years and 19-49 years and travelers aged ≥19 years), herpes zoster vaccination (all ages), and HPV vaccination among females aged 19-26 years. Vaccination coverage also varied by citizenship status and years living in the United States. NHIS data indicate that many adults remain unprotected against vaccine-preventable diseases. Coverage for the adult age-appropriate composite measures was low in all age groups. Individual adult vaccination coverage remained low as well, but modest gains occurred in vaccination coverage for hepatitis B (among adults aged ≥19 years and HCP aged ≥19 years), and HPV (among males aged 19-26 years and Hispanic females aged 19-26 years). Coverage for other vaccines and groups with Advisory Committee on Immunization Practices vaccination indications did not improve from 2017. Although HPV vaccination coverage among males aged 19-26 years and Hispanic females aged 19-26 years increased, approximately 50% of females aged 19-26 years and 70% of males aged 19-26 years remained unvaccinated. Racial/ethnic vaccination differences persisted for routinely recommended adult vaccines. Having health insurance coverage, having a usual place for health care, and having ≥1 physician contacts during the preceding 12 months were associated with higher vaccination coverage; however, these factors alone were not associated with optimal adult vaccination coverage, and findings indicate missed opportunities to vaccinate remained. Substantial improvement in adult vaccination uptake is needed to reduce the burden of vaccine-preventable diseases. Following the Standards for Adult Immunization Practice (https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html), all providers should routinely assess adults' vaccination status at every clinical encounter, strongly recommend appropriate vaccines, either offer needed vaccines or refer their patients to another provider who can administer the needed vaccines, and document vaccinations received by their patients in an immunization information system.
Identifiants
pubmed: 33983910
doi: 10.15585/mmwr.ss7003a1
pmc: PMC8162796
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-26Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were reported.
Références
JAMA. 2002 Mar 13;287(10):1288-94
pubmed: 11886320
J Travel Med. 2001 Jan;8 Suppl 1:S3-8
pubmed: 11182611
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Am J Epidemiol. 2012 Apr 15;175(8):827-37
pubmed: 22403807
Mayo Clin Proc. 2007 Nov;82(11):1341-9
pubmed: 17976353
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):718-723
pubmed: 31437143
Vaccine. 2011 May 17;29(22):3850-6
pubmed: 21459173
Am J Prev Med. 2019 Oct;57(4):458-469
pubmed: 31473066
Am J Med. 2005 Oct;118 Suppl 10A:58S-62S
pubmed: 16271543
MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61(4):66-72
pubmed: 22298302
Public Health Rep. 2013 Nov-Dec;128(6):498-509
pubmed: 24179261
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
Vaccine. 2013 Aug 20;31(37):3928-35
pubmed: 23806243
Pediatrics. 2008 Oct;122(4):718-25
pubmed: 18829793
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
MMWR Surveill Summ. 2013 Oct 25;62(4):1-28
pubmed: 24157710
Am J Epidemiol. 2013 Nov 1;178(9):1478-87
pubmed: 24008912
J Travel Med. 2002 Jan-Feb;9(1):10-6
pubmed: 11962352
MMWR Morb Mortal Wkly Rep. 2018 Apr 20;67(15):455-458
pubmed: 29672472
MMWR Morb Mortal Wkly Rep. 1982 Jun 25;31(24):317-22, 327-8
pubmed: 6811846
Vaccine. 2013 May 1;31(19):2348-57
pubmed: 23523408
MMWR Morb Mortal Wkly Rep. 2012 Sep 28;61:758-63
pubmed: 23013721
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1709-11
pubmed: 22189894
J Travel Med. 2013 May-Jun;20(3):194-202
pubmed: 23577866
MMWR Morb Mortal Wkly Rep. 2012 Sep 28;61:753-7
pubmed: 23013720
MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9
pubmed: 23051612
Am J Prev Med. 2015 Jun;48(6):647-61
pubmed: 25890684
MMWR Recomm Rep. 2010 Dec 10;59(RR-11):1-18
pubmed: 21150868
Vaccine. 2009 Feb 5;27(6):882-7
pubmed: 19071175
MMWR Morb Mortal Wkly Rep. 2014 Feb 7;63(5):110-2
pubmed: 24500291
Clin Infect Dis. 2020 Jun 10;70(12):2496-2502
pubmed: 31344229
MMWR Recomm Rep. 2018 Jan 12;67(1):1-31
pubmed: 29939980
J Natl Med Assoc. 2006 Jul;98(7):1089-94
pubmed: 16895277
MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5
pubmed: 25233284
Influenza Other Respir Viruses. 2018 Nov;12(6):808-813
pubmed: 30028081
Infect Control. 1985 Jan;6(1):24-31
pubmed: 3871428
Vaccine. 2017 May 25;35(23):3104-3115
pubmed: 28457673
MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33; quiz CE1-4
pubmed: 17159833
J Immigr Minor Health. 2008 Feb;10(1):37-44
pubmed: 17952600
Am J Epidemiol. 1982 Jan;115(1):26-39
pubmed: 7055128
MMWR Morb Mortal Wkly Rep. 2010 Oct 15;59(40):1302-6
pubmed: 20948508
MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45
pubmed: 22108587
J Pediatr. 2019 Mar;206:33-41.e1
pubmed: 30448270
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S455-64
pubmed: 26382294
Drugs. 2012 Jan 1;72(1):35-48
pubmed: 22191794
MMWR Surveill Summ. 2016 Feb 05;65(1):1-36
pubmed: 26844596
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31
pubmed: 25144544
MMWR Recomm Rep. 2020 Jul 03;69(5):1-38
pubmed: 32614811
Vaccine. 2003 Mar 28;21(13-14):1486-91
pubmed: 12615445
Am J Public Health. 2003 Jan;93(1):130-7
pubmed: 12511402
MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19
pubmed: 24352112
MMWR Morb Mortal Wkly Rep. 2012 Nov 2;61(43):883-5
pubmed: 23114256
MMWR Recomm Rep. 1997 Apr 4;46(RR-8):1-24
pubmed: 9132580
Am J Med. 2008 Jul;121(7 Suppl 2):S28-35
pubmed: 18589065
Am J Prev Med. 2018 Oct;55(4):517-523
pubmed: 30135039
Pediatrics. 2011 Nov;128(5):830-9
pubmed: 22007006
Arch Intern Med. 2001 Dec 10-24;161(22):2702-8
pubmed: 11732935
Am J Prev Med. 2016 Dec;51(6):1015-1026
pubmed: 27866594
J Travel Med. 2005 Jan-Feb;12(1):26-35
pubmed: 15996464
Am J Med. 2016 Jun;129(6):636.e1-636.e11
pubmed: 26551981
Ann Intern Med. 2014 Feb 4;160(3):161
pubmed: 24658693
P T. 2016 Aug;41(8):492-506
pubmed: 27504066
MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
pubmed: 20689501
MMWR Morb Mortal Wkly Rep. 2014 Jan 31;63(4):69-72
pubmed: 24476977
Clin Infect Dis. 2020 Dec 17;71(10):e571-e579
pubmed: 32193542
MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23
pubmed: 16708058
MMWR Morb Mortal Wkly Rep. 2015 Sep 04;64(34):944-7
pubmed: 26334788
Ann Fam Med. 2010 Nov-Dec;8(6):507-10
pubmed: 21060120
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
Am J Prev Med. 1999 Apr;16(3):173-7
pubmed: 10198654
MMWR Morb Mortal Wkly Rep. 2020 Feb 07;69(5):133-135
pubmed: 32027627
J Adolesc Health. 2009 Nov;45(5):528-31
pubmed: 19837361
Vaccine. 2018 Feb 1;36(6):890-898
pubmed: 29329685
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075
pubmed: 31751323
J Gen Intern Med. 2006 Apr;21(4):346-51
pubmed: 16686810
MMWR Recomm Rep. 2019 Aug 23;68(3):1-21
pubmed: 31441906
Ann Intern Med. 2010 May 4;152(9):555-60
pubmed: 20439573
MMWR Morb Mortal Wkly Rep. 2011 Jan 14;60(1):13-5
pubmed: 21228763
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
MMWR Morb Mortal Wkly Rep. 2011 Aug 19;60(32):1073-7
pubmed: 21849963
J Travel Med. 2004 Jul-Aug;11(4):260-1
pubmed: 15541232
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
Vaccine. 2018 Nov 19;36(48):7408-7414
pubmed: 30420121
Am J Health Behav. 2007 Jul-Aug;31(4):434-45
pubmed: 17511578
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702
pubmed: 31415491
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
Vaccine. 2013 Jun 19;31(28):2937-46
pubmed: 23643629
N Engl J Med. 2004 Aug 5;351(6):575-84
pubmed: 15295050
Am J Prev Med. 2018 Sep;55(3):308-318
pubmed: 30054198
Am J Prev Med. 2006 Oct;31(4):281-5
pubmed: 16979451
Vaccine. 2019 Sep 3;37(37):5509-5512
pubmed: 31400911
Public Health Rep. 2014 Mar-Apr;129(2):115-23
pubmed: 24587544
MMWR Recomm Rep. 2006 Dec 15;55(RR-17):1-37
pubmed: 17167397
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S412-25
pubmed: 26297451
MMWR Morb Mortal Wkly Rep. 2007 Oct 19;56(41):1080-4
pubmed: 17947967
MMWR Morb Mortal Wkly Rep. 2018 Sep 28;67(38):1050-1054
pubmed: 30260944
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):591-593
pubmed: 32407298
MMWR Morb Mortal Wkly Rep. 2012 Jun 29;61(25):468-70
pubmed: 22739778
J Adolesc Health. 2007 May;40(5):398-404
pubmed: 17448396
J Community Health. 1988 Spring;13(1):53-64
pubmed: 3360981
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2
pubmed: 20508594
MMWR Recomm Rep. 1991 Nov 22;40(RR-13):1-25
pubmed: 1835756
Clin Infect Dis. 2020 Jun 10;70(12):2484-2492
pubmed: 31402387
J Adolesc Health. 2009 Jun;44(6):561-7
pubmed: 19465320
Am J Prev Med. 2014 Dec;47(6):722-33
pubmed: 25300733
Public Health Rep. 2011 Jul-Aug;126 Suppl 2:39-47
pubmed: 21812168
Am J Prev Med. 2001 Jan;20(1):21-5
pubmed: 11137770
Am J Prev Med. 2005 Dec;29(5):412-20
pubmed: 16376704
J Am Geriatr Soc. 2006 Feb;54(2):303-10
pubmed: 16460383
MMWR Suppl. 2014 Apr 18;63(1):7-12
pubmed: 24743661
Am J Infect Control. 2011 Aug;39(6):488-94
pubmed: 21288599
Vaccine. 2016 Mar 18;34(13):1604-1610
pubmed: 26854907
Am J Epidemiol. 2009 Sep 1;170(5):650-6
pubmed: 19625341
Clin Microbiol Rev. 2008 Jul;21(3):426-34
pubmed: 18625679